Vancouver, British Columbia-March 16, 2026 - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE:8BN) (the "Company" or "Optimi"), a commercial-stage
First Patients of 2026 Treated Outside of Sponsor-Led Clinical Trials Under Australia's Regulated FrameworkVancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - Optimi Health Corp. (CSE:...
Naturally-Derived 5 mg Psilocybin Capsules Mark the Company's Second Drug in Market Under Australia's Authorised Prescriber SchemeVancouver, British Columbia--(Newsfile Corp. - February 19, 2026) - Optimi...
MDMA-assisted therapy for PTSD delivered through Optimi's direct-to-clinic supply model under Australia's Authorised Prescriber SchemeVancouver, British Columbia--(Newsfile Corp. - February 17, 2026) -...
(February 9, 2026) - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychoactive
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical...
(January 26, 2026) - Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug
Australia's Department of Health has issued import permits for Optimi's MDMA and psilocybin capsules for use under the Authorised Prescriber SchemeVancouver, British Columbia--(Newsfile Corp. - January...
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a leading producer of prescribed psychedelic treatments...
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA...